Category: Health and wellness

NEW YORK, April 1, 2019 /PRNewswire/ — Cannabis has become one of the most controversial topics on many countries” political agendas. Cannabis is still internationally illegal under regulatory statutes, but clinical trials and research have led countries to explore opportunities within the medical cannabis market. However, the recreational market is still widely being heavily enforced. Nonetheless, certain regions have moved to decriminalize, or even fully legalize, recreational cannabis use. Unlike marijuana, hemp”s main component is CBD. While THC provides psychoactive effects to consumers, CBD does not induce psychoactive effects, but provide a therapeutic and relaxing effect akin to that of THC. Furthermore, because CBD does not provide any psychoactive effects, many countries have allowed personal use of the CBD as long as it contains less than 0.3% THC. According to data compiled by Hemp Business Journal, a division of New Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million and is expected to grow to reach USD 1.9 Billion by 2022. Additionally, the market is projected to grow at a CAGR of 14.4% throughout the forecast period from 2018 to 2022. Overall, the industry is expected to be driven by increasing sales in the hemp-derived CBD and industrial application segments. Chineseinvestors.com Inc. (OTC: CIIX), Tilray, Inc. (NASDAQ: TLRY), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aphria Inc. (NYSE: APHA) (TSX: APHA)

In 2017, the hemp-derived CBD product segment delivered USD 190 Million in sales, accounting for 23% of the overall market. The hemp food segment, which delivered USD 137 Million in sales, accounted for 17% of the hemp market that same year. By 2022, the food segment is expected to reach USD 212 Million as the segment is seeing major investments, primarily by large beverage corporations looking to enter into the cannabis-infused beverage industry. Many are looking to use cannabidiol, or CBD, to create therapeutic non-alcoholic drinks for consumers. However, CBD still remains popular among consumers in forms of capsules, oils, and flower itself. While the beverage industry is growing rapidly, other forms of CBD-based products are also seeing large growth. ‘The fact that a consumer-cannabis product has captured the attention of so many folks—from customers on the street to executives in the boardroom—reveals something far more lasting than whatever may come from this beverage product, even if it never launches,’ said Ben Curren, Chief Executive Officer and Founder of Green Bits. ‘What it reveals is that now, you and I and millions of people can picture this: the substance that once was considered the nation”s most deadly, the very banner of America”s war on drugs, might someday soon be ‘Brought to You By Coke,’ and not just as a social lubricant but as a sports recovery product applicable to an even wider audience.’

Chineseinvestors.com Inc. (OTCQB: CIIX) just announced breaking CBD news this morning that, ‘that its wholly owned foreign enterprise , CBD Biotechnology Co. Ltd. (‘CBD Biotech’), will participate in the 29th Vietnam International Trade Fair (Vietnam Expo) at the Hanoi International Exhibition Center (ICE) being held on April 10-13, 2019 in Hanoi.

As a featured exhibitor at the Vietnam Expo, CBD Biotech will introduce the new concept of ‘hemp plant extracting’ and cosmetics.  CBD Biotech will exhibit its self-branded hemp-infused skincare line as well as its hemp wine.  CBD Biotech is one of the first companies to offer skincare products infused with hemp oil and hemp leaf extract in China. Focused on building new markets for industrial hemp products in throughout Asia, this expo will allow CBD Biotech to  explore possible partnership opportunities for the Vietnamese market.

‘The Vietnam Expo continues to be an important business destination to build bridges for trade promotion, foreign relations, facilitating commerce and attracting trade between Vietnamese and foreign enterprises,’ said Ms. Summer Yun, CEO of CBD Biotechnology Co. Ltd. ‘A pioneer in the Chinese market for hemp-infused skincare products and a Chinese originator of ‘hemp plant extracting’ in combination with skincare, CBD Biotech”s participation in this year”s Vietnam Expo will give our brand the exposure needed to become an influencer within the Asian market. We anticipate creating lucrative export opportunities and exploring possible expansion to more Southeast Asian countries and members of ASEAN.’

The Vietnam Expo, one of Vietnam”s largest, most influential international exhibitions,

is hosted by the Ministry of Industry and Trade of Vietnam. This year the event  will showcase 760 companies with over 1,000 international booths, with 35% of the companies being foreign and 65% Vietnam-based. The event provides foreign exhibitors the opportunity to educate Vietnamese business professionals regarding global trends and provides attendees the opportunity to purchase new products and learn about new technologies and investment opportunities.

CBD Biotech”s current line of skincare products features the Popular Series which includes hemp peptide concentrate liquid, aqua bio-magnetic mask and hemp hyaluronic acid, the Live Oxygen Series which includes oxygen cleansing foam, oxygenated water and live oxygen cream, the Plant Series which includes Huanyan tone-up cream, aqua double moisturizer and peptide mineral essence, and the New Products Series which includes hemp eye pads, horse oil soap and hemp eye cream.

About ChineseInvestors.com – Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products. For more information, visit ChineseInvestors.com.’

Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents. Tilray, Inc. recently announced that it had entered into a definitive agreement, pursuant to which Tilray will acquire all of the issued and outstanding securities of FHF Holdings Ltd. from Compass Group Diversified Holdings, LLC (NYSE:CODI) and other shareholders of Manitoba Harvest. Under the terms of the Agreement, Tilray will acquire Manitoba Harvest on a cash and debt-free basis, for an aggregate purchase price, including cash and class 2 Common Stock in the capital of Tilray, of up to CAD 19 Million pending the achievement of certain milestones after the closing of the Transaction. Together, Tilray and Manitoba Harvest plan to grow both companies” revenue while bringing nutritious hemp foods and supplements to more households across the U.S. and Canada. The acquisition will expand Tilray”s product portfolio into the natural foods category and bring Manitoba Harvest expertise in working with cannabinoids, including cannabidiol (CBD). By leveraging Manitoba Harvest”s established distribution network, Tilray plans to accelerate its expansion into the U.S. and Canadian markets, where legal, for CBD products. Manitoba Harvest also brings to Tilray an experienced team and manufacturing capabilities, including the addition of two high quality BRC AA+ certified manufacturing facilities as well as significant sales and distribution capabilities. ‘Tilray”s acquisition of Manitoba Harvest is a milestone for the cannabis industry. It builds on the strategic partnerships we have formed with consumer brand industry leaders and demonstrates our track record of disrupting the global pharmaceutical, alcohol, CPG, and functional food and beverage categories,’ said Brendan Kennedy, Tilray President and Chief Executive Officer. ‘We”re excited to work with Manitoba Harvest to develop and distribute a diverse portfolio of branded hemp-derived CBD food and wellness products in the U.S. and Canada.’

Canopy Growth Corporation (NYSE: CGC) (TSX: WEED) is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth Corporation and Sequential Brands Group, Inc. (NASDAQ: SQBG) recently announced that Martha Stewart had joined the Company in an advisory role to assist with developing and positioning a broad new line of product offerings across multiple categories. With decades of success in publishing, broadcasting, online and merchandising, Martha Stewart has firmly cemented herself as one of the most well-respected businesswomen in the United States. Along with a deep understanding of what consumers in the United States and around the world want, Martha has been one of the most vocal advocates for animals, championing the health and wellness of pets and farm animals alike. With several clinical trials underway, Canopy Growth will be leaning on Martha”s vast knowledge of consumer products while exploring the effectiveness of CBD and other cannabinoids as they relate to improving the lives of both humans and animals. As previously reported in January 2019, Canopy Growth has developed diverse product offerings specific to hemp-derived CBD and the Company looks forward to working closely with Martha Stewart as they further develop and introduce these products to market in the future. Canopy Growth previously reported that it will invest between USD 100 Million and USD 150 Million in a hemp industrial park in New York State with an intended purpose of being the Company”s first hemp facility in the United States. ‘As soon as you hear the name Martha, you know exactly who we”re talking about,’ shared Canopy Growth Chairman and co-Chief Executive Officer , Bruce Linton. ‘Martha is one of a kind and I am so excited to be able to work alongside this icon to sharpen our CBD product offerings across categories from human to animal.’

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) is a globally diversified and vertically integrated cannabis company with a presence across four continents. Recently, Cronos Group Inc. and Ginkgo Bioworks Inc., the organism company, announced a landmark partnership to produce cultured cannabinoids. Using its platform technology for organism design and development, Ginkgo will complement Cronos Group”s technologies for producing a full spectrum of cannabinoids. As part of this unprecedented deal, Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo”s achievement of certain production milestones. As two of the leading companies in their respective industries, Cronos Group and Ginkgo believe that they are best-suited to unlock the potential of innovation in the cannabis industry. Cronos Group brings a deep understanding of the plant”s biological structure and function, while Ginkgo brings 10 years of experience designing microorganisms for the production of cultured products across pharmaceuticals, agriculture, flavors, fragrances, and more. ‘Cronos Group is building the world”s most innovative cannabinoid platform,’ said Mike Gorenstein, Chief Executive Officer of Cronos Group. ‘The potential uses of cannabinoids are vast, but the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent, and scalable production of a full spectrum of cannabinoids, not just THC and CBD. We are thrilled to partner with Ginkgo; their biological engineering capabilities and disruptive technology platform are unrivaled. Together we can revolutionize the cannabis industry.’

Aphria Inc. (NYSE: APHA) (TSX: APHA) is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Aphria Inc. and Rapid Dose Therapeutics Inc. (CSE: DOSE) recently announced that they have expanded the scope of their previously announced agreement expanding the territory where Aphria has been granted exclusive preferred rights to license, manufacture, distribute and sell RDT”s QuickStrip™ innovative, proprietary delivery technology for the cannabis market to Germany. RDT”s proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers a smoke-free choice to consumers. Aphria expects to produce and distribute CBD-only Quickstrips™ in Germany by Spring 2019. As part of the Agreement, Aphria maintains the option to add future international markets as the opportunity in those markets evolve. ‘Germany is one of the most sought-after cannabis markets today, and Aphria continues to take a comprehensive approach to ensure a leading presence in the country as the opportunity evolves,’ said Jakob Ripshtein, President of Aphria. ‘Aphria is committed to bringing advanced products and innovations to cannabis markets around the world, and this agreement with RDT will enable us to bring QuickStrip™ technology to the German market and offer a unique nutraceutical product that delivers a consistent dosage.’

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ”Site”) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Chineseinvestors.com Inc. financial and corporate news dissemination, FinancialBuzz.com expects to be compensated three thousand five hundred dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: www.FinancialBuzz.com

FinancialBuzz.com News Commentary

[[[tasteofexc

Read Full Article

  • EQT invests in MHC Asia, a healthcare benefits administrator in Southeast Asia powered by a strong management team
  • MHC Asia aggregates health, wellness and lifestyle data to provide actionable insights that enable organizations to customize their health and wellness offerings with the aim to improve the quality of life of their employees and dependents and maintain an optimal balance between cost and quality of care  
  • EQT is partnering with the Founder and CEO, Dr Low Lee Yong and management to drive MHC”s next phase of growth

The EQT Mid Market Asia III Fund (‘EQT’) has today announced its investment in MHC Asia Holdings Pte. Ltd. (‘MHC’ or ‘the Company’). Founded in 1994, MHC is a leading healthcare benefits administrator in Southeast Asia, offering approximately 800,000 corporate patients access to panel of over 1,200 clinics and processing about 1.8 million medical claims annually.

Since its founding years, MHC has been striving to positively impact corporate managed healthcare in Singapore and surrounding regions. Equipped with strong artificial intelligence and analytical capabilities, MHC is able to identify trends early and intelligently optimize healthcare costs and quality of care. As such, MHC maximizes value creation for its business partners beyond the traditional third-party administration, medical claims processing and adjudication service.

Going forward, the strategy is to further develop MHC”s client portfolio and regional presence, invest further in technology and strengthen its position as the preferred corporate health benefits solution provider. The growth of the Company will also be supported by EQT”s Industrial Network and a board of directors with significant relevant experience and network.

Dr. Low Lee Yong, CEO of MHC Asia, said: ‘We were courted by different institutional investors, but we picked EQT to be our strategic investor and partner because we were very impressed by the EQT team. We share the same vision and passion about making a difference to transform and simplify healthcare with technology. What an exciting way to celebrate our 25th anniversary by having a trusted and friendly partner to support our growth and regional expansion!’

Eric Koh, COO of MHC Asia, said: ‘We want to delight our customers and give them insights that will enable them to make the optimal decisions. EQT gives us the ability to do more, do better and do smarter.’

Brian Chang, Partner at EQT Partners and Investment Advisor to the EQT Mid Market Asia III Fund, concluded: ‘EQT is impressed with MHC”s leading position and its innovative, technology-driven approach to go beyond the traditional role of a typical healthcare benefits administrator. EQT is fully committed to supporting MHC”s dynamic management team to continue delivering consistent growth through its various expansion strategies.’

Contact
Brian Chang, Partner at EQT Partners, Investment Advisor to the EQT Mid Market Asia III Fund, +65 6595 1830
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT

EQT is a leading investment firm with more than EUR 61 billion in raised capital across 29 funds and around EUR 40 billion in assets under management. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtpartners.com

About MHC

MHC is a leading healthcare benefits administrator in Southeast Asia. Founded in 1994 and headquartered in Singapore, the Company serves several insurer and corporate clients and has approximately 800,000 corporate employees as members.

More info: www.mhcasia.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt-ab/r/eqt-invests-in-mhc-asia–a-leading-healthcare-benefits-administrator-in-southeast-asia,c2777181

The following files are available for download:

https://mb.cision.com/Main/87/2777181/1017526.pdf

Press release EQT Mid Market Asia III MHC 190401

 

STOCKHOLM, April 1, 2019 /PRNewswire/ —

[[[tasteofexc

Read Full Article

The study examined past 30-day smoking abstinence rates three months after initial JUUL product purchase among a sample of 15,456 adult smokers aged 21+ years.  Abstinence was defined as zero puffs of a combustible cigarette in the past 30 days.  Results showed that 47.1 % of the 9,272 survey participants who completed the 3-month follow-up assessment had completely abstained from smoking for the prior 30 days.  Overall, 28.3% of all 15,456 participants who began the study abstained from smoking during the reporting period.

Importantly, the study also found that participants who had exclusively used non-tobacco flavors Mango, Cucumber, Fruit, Creme, Menthol, and Mint were 30% more likely to have abstained from smoking at three months compared to those who exclusively used tobacco flavors.  In addition to being the most commonly used flavors, smokers who primarily used Mint or Mango JUULpods in the 30 days prior to the 3-month assessment were 37% and 26% more likely, respectively, to have not smoked any cigarettes in the previous 30 days compared to primary users of Virginia Tobacco flavored JUULpods.

In total, the study identified eight variables that were significant in predicting the likelihood of past 30-day smoking abstinence after using JUUL products for three months, including frequency of JUUL use, smoking heaviness and duration, place of purchase, and purchase with intent to stop smoking completely.  Future analyses will include data from the same participants at 6 and 12-month follow-up assessments after initiating use of JUUL products.

‘The results of this study indicate that close to half of adult smokers who used a JUUL product for three months had abstained from smoking for the past 30 days, with even higher rates of abstinence observed among those who primarily used JUULpods in non-tobacco flavors,’ said Dr. Neil McKeganey, Director of the Centre for Substance Use Research (Glasgow, UK).  ‘Although additional follow-up research is needed, flavored JUULpods have been shown to have a significant impact in getting smokers to switch and ultimately abstain from cigarettes over a period of time.  We will continue to track this and other variables impacting smokers” likelihood of abstaining from cigarette use, including collecting additional survey data at both the 6 and 12-months mark after initiating JUUL use.’

‘Our mission is to improve the lives of the world”s one billion smokers by eliminating cigarettes and we are encouraged by these study findings that approximately half of smokers switch away from combustible cigarettes after three months of JUUL use,’ said Erik Augustson, Ph.D., MPH Senior Director of Behavioral Research at JUUL Labs. ‘We are committed to continuing to research the potential public health impact of our products and have over 100,000 participants enrolled in behavioral studies across the world, where we are collecting data on a range of topics, including factors that improve the likelihood of completely switching from combustible cigarettes and the role responsible flavors may play in that process.’

About the Study:

JUUL Labs commissioned and funded the Centre for Substance Use Research (CSUR) to independently design and administer the survey, and analyze and report the study results. Individuals were invited to participate in this study through email invitations to e-commerce customers and through inserts in JUUL starter kits distributed in retail stores across the U.S.  Eligible individuals were U.S. adults aged 21 years and older who had smoked at least 100 cigarettes in their lifetime, and had purchased their first JUUL starter kit from a U.S. retail store or through JUUL”s e-commerce store at www.juul.com within the past seven days.

About JUUL Labs, Inc.

JUUL Labs is committed to improving the lives of the world”s one billion adult smokers by eliminating cigarettes, the leading cause of preventable death in the world.  JUUL Labs” products are designed to help smokers switch.

JUUL Labs is equally committed to combating underage use of nicotine and tobacco products. The company launched a comprehensive action plan to address youth access, appeal, and use that includes restricting the sale of certain flavored JUULpods from traditional retail, enhancing our online age-verification, improving retailer compliance, eliminating use of Facebook and Instagram accounts and utilizing technology-based solutions to prevent youth use. We also actively support Tobacco 21 legislation to raise the minimum-purchasing age for all tobacco products, including vapor products, to 21. For more information on our mission and youth prevention initiatives, please visit https://newsroom.juul.com/.

Media Contacts
Press@juul.com

Photo – https://mma.prnewswire.com/media/844128/juul1.jpg  
Photo – https://mma.prnewswire.com/media/844129/juul.jpg

SAN FRANCISCO, April 1, 2019 /PRNewswire/ — The Harm Reduction Journal recently published results of a behavioral study examining the role of JUUL use, JUULpod flavors, and other factors in predicting past 30-day abstinence from cigarette smoking among new users of JUUL products.

[[[tasteofexc[[[tasteofexc

Read Full Article

Don”t miss out on business opportunities in Latin America Pharmaceutical Excipients Market

Growth in this market is driven by the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; increasing focus of MNCs on investing in the pharmaceutical and healthcare sectors in Latin America; growing pricing pressures; rapid growth in aging population & the subsequent increase in the prevalence of related diseases; and the availability of local and government funding for R&D activities. 

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41302221

Browse in-depth TOC on ‘Latin America Pharmaceutical Excipients Market

28 – Tables
11 – Figures   
281 – Pages  

By functionality, the filler & diluents segment accounted for the largest share of the Latin America Pharmaceutical Excipients Market

The Latin America Pharmaceutical Excipients Market, by functionality, is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disintegrants, lubricants & glidants, preservatives, emulsifiers & solubilizers, and other functionalities. The fillers & diluents segment accounted for the largest market share in 2018. The increased use of fillers & diluents in the development and production of solid dosage form and the wide applications of diluents in the wet granulation and direct compression process for tablet formulation are driving the growth of the fillers & diluents segment.

Request Sample Pages: 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=41302221

Mexico to dominate the Latin America Pharmaceutical Excipients Market during the forecast period

In 2018, Mexico dominated the Latin America Pharmaceutical Excipients Market, followed by Argentina. Over the past few years, Mexico has become an attractive destination for investment in the pharmaceutical industry due to its large pharmaceutical production and consumption capacity and the improved regulatory framework. Growing pharmaceutical production and consumption, increasing investments by MNCs, and improved regulatory framework are the major factors driving the growth of the pharmaceutical excipients market in Mexico.

Prominent players in the Latin America Pharmaceutical Excipients Market are DowDuPont (US), Roquette (France), Ashland (US), BASF (Germany), and Kerry Group (Ireland).

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=41302221

Browse Adjacent Markets @ Pharmaceuticals Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/latin-america-pharmaceutical-excipient-market.asp

Visit Our Website: https://www.marketsandmarkets.com

https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

CHICAGO, March 12, 2019 /PRNewswire/ — According to the new market research report Latin America Pharmaceutical Excipients Market by Functionality (Fillers, Coating, Disintegrants, Binders, Lubricants, Preservatives, Emulsifying Agents, Lubricants, Glidants, Diluents), Country (Mexico, Argentina, Columbia, Peru) – Forecast to 2024′, published by MarketsandMarkets™, the Latin America Pharmaceutical Excipients Market is projected to reach USD 579 million by 2024 from USD 403 million in 2019, at a CAGR of 7.5%.

[[[tasteofexc

Read Full Article

VALLEY COTTAGE, New York, Feb. 21, 2019 /PRNewswire/ — Sales of smart pill boxes and bottles are likely to reach around 800 thousand in 2019. According to a new analytical research study by Future Market Insights (FMI), smart pill boxes and bottles market will remain a high growth-low volume landscape over the course of next few years. Over 43% of total sales will be accounted by smart pill boxes. The report envisages a higher rate of adoption for smart pill bottles.

Almost 70% of adult patients are observed to discontinue or manipulate drug therapy, resulting in non-adherence to prescribed medication. The study opines that this directly adds to the economic burden on healthcare delivery system in form of emergency cases and hospitalization.

Smart pill boxes and bottles are increasingly being perceived as a potential solution to such challenges posed by increased healthcare delivery costs. Significance of medication adherence continues to rise with increasing prevalence of chronic conditions, propelling demand for smart pill boxes and bottles.

Request a Sample Report with Table of Contents and Figureshttps://www.futuremarketinsights.com/reports/sample/rep-gb-1710

Dementia and geriatric care remain the key application areas of smart pill boxes and bottles, according to the report. More than 80% of sales is accounted by aging patients and dementia-afflicted population. Cancer management is likely to emerge lucrative in terms of applicability in coming years.

With surging demand for high-quality healthcare delivery, senior care centers, hospitals, long-term care centers, and homecare settings are accelerating adoption of medication dispensers, thereby elevating the revenue growth of smart pill boxes and bottles market. Some of the leading companies are actively involved in the development of advanced technology medication dispensing devices with zero error risks during medication.

Buy this report @ https://www.futuremarketinsights.com/checkout/1710

Home care settings maintain the highest consumption share in smart pill boxes and bottles market that roughly equates 65% of total sales. Almost a fifth of smart pill boxes and bottles sold are installed at seniors care and assisted living centers. FMI”s analysis indicates that long-term care centers are also creating promising market opportunities for smart pill boxes and bottles manufacturers and distributors.

North America continues to reign supreme owing to early adoption of advanced technology enabled smart pill boxes and bottles, accounting for more than a third of the global market revenue. European market for smart pill boxes and bottles also represents a substantial volume share, majorly driven by German patients. South and East Asian regions are briskly developing high-potential markets for manufacturers and distributors of smart pill boxes and bottles, says the report.

Preview Analysis of Smart Pill Boxes & Bottles Market is segmented by (Type – Smart Pill Box & Smart Pill Bottles; Indication – dementia, Parkinson”s disease, cancer management, diabetes care, geriatric care, disability & others; Distribution channel – seniors care & assisted living, long term care centers & home care;) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028: https://www.futuremarketinsights.com/reports/smart-pill-boxes-bottles-market

The vendor landscape of smart pill boxes and bottles market remains fairly consolidated and competitive, as Tier 1 manufacturers continue to account for a majority of share in the market in terms of volume. While dominance of Koninklijke Philips N.V., PharmRight Corporation & Livi, and AdhereTech prevails in smart pill boxes and bottles market, the report finds that the competition among these players is characterized by product innovation, new launches, and technological advancements.

FMI has tracked market performance for a decade-old projection period – 2018-2028. For exclusive insights on the various other aspects of smart pill boxes and bottles market landscape, write to the analyst at press@futuremarketinsights.com

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with youhttps://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1710

More from Healthcare, Pharmaceuticals and Medical devices Market Insights Market Intelligence:

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Browse More Healthcare, Pharmaceuticals and Medical devices Market Insights

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44(0)20-7692-8790
Sales: sales@futuremarketinsights.com 
Press Office: Press@futuremarketinsights.com 
Blog: Market Research Blog 
Website: https:www.futuremarketinsights.com

Over 6 in 10 Smart Pill Boxes & Bottles Sell in Home Care Settings, Dementia & Geriatric Care Spur Demand Growth

[[[tasteofexc

Read Full Article

The North America market would dominate the Global Second Generation Pens Market by Region in by 2024, growing at a CAGR of 9.7 % during the forecast period. The Europe market is expected to witness a CAGR of 10.2% during (2018 – 2024). Additionally, The Asia Pacific market is expected to witness a CAGR of 11.9% during (2018 – 2024). Asia Pacific would be the fastest growing market, which offers lucrative opportunities for the market growth, due to its substantial population base and growing diabetic patients. On the other hand, affordability of the Insulin pens also propels the market growth in the region.

The Hospitals & Clinics market dominated the Global Smart Insulin Pen Market by End User in 2017. The Ambulatory Surgical Centers market is expected to witness a CAGR of 10.6% during (2018 – 2024). The major factors that drive the growth of the market include growing diabetic population, lower cost of insulin pumps, and painless injections.

Access Full Report: https://www.kbvresearch.com/smart-insulin-pen-market/

The Prefilled market dominated the Global Smart Insulin Pen Market by Usability in 2017, and would achieve a market value of $64,759.4 Thousand by 2024. The Reusable market is expected to witness a CAGR of 10.7% during (2018 – 2024).

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Companion Medical Inc., Digital Medics Ptd Ltd., Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co., Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Emperra GmbH E-Health Technologies, Jiangsu Delfu medical device Co. Ltd., Bigfoot Biomedical.

Global Smart Insulin Pen Market Segmentation

By Product 

  • Second Generation Pens
    o   USB Connected Smart Insulin Pen
    o   Bluetooth-Enabled Smart Insulin Pen
  • First Generation Pens

By Usability

  • Prefilled
  • Reusable

By End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home care settings

 By Geography

  • North America
    o   US
    o   Canada
    o   Mexico
    o   Rest of North America 
  • Europe
    o   Germany
    o   UK
    o   France
    o   Russia
    o   Spain
    o   Italy
    o   Rest of Europe 
  • Asia Pacific
    o   China
    o   Japan
    o   India
    o   South Korea
    o   Singapore
    o   Malaysia
    o   Rest of Asia Pacific 
  • LAMEA
    o   Brazil
    o   Argentina
    o   UAE
    o   Saudi Arabia
    o   South Africa
    o   Nigeria
    o   Rest of LAMEA

Companies Profiled

  • Companion Medical Inc.
  • Digital Medics Ptd Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Diamesco Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Insulet Corporation
  • Emperra GmbH E-Health Technologies
  • Jiangsu Delfu medical device Co. Ltd.
  • Bigfoot Biomedical

Unique Offerings from KBV Research

  • Exhaustive coverage  
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

About Us:

Knowledge Based Value Research is a global brand and consulting firm serving all kinds of business verticals, government and non-governmental organizations, and not-for-profit organizations. Our motto is to extend our services that will have a lasting impact on our clients who trust us with their business goals.

Our aim is to transform and customize our services to address the fast changing business needs of our clients. With innovative methods, we seek to empower our research tools with new capabilities that would eventually bring about customer delight, as we understand that businesses evolve.

Media Contact:

Mr. Alan D”Souza
KBV Research
244 Fifth Avenue, Suite 1407
New York, N.Y. 10001
United States (U.S)
Tel: +1 (646) 661-6066
Email: query@kbvresearch.com

 

NEW DELHI, Feb. 21, 2019 /PRNewswire/ — According to a new report Global Smart Insulin Pen Market, published by KBV research, The Global Smart Insulin Pen Market size is expected to reach $117.3 Million by 2024, rising at a market growth of 10.2% CAGR during the forecast period. The demand is due to rapidly rising number of diabetic patients, and cost-effectiveness of the smart insulin pens. In addition, the simple functioning and accurate delivery of appropriate dosing adds to the demand.

[[[tasteofexc

Read Full Article

FinancialBuzz.com News Commentary

Europe and the LATAM region are attractive regions for many companies to establish operations. Europe”s overall cannabis market is projected to reach USD 66.8 Billion within the next five years, while the LATAM region is expected to reach USD 12.7 Billion in sales by 2028, according to Prohibition Partners. The research notes that several European countries have passed medical marijuana legislation recently, and there is a 50% chance a few more could pass recreational laws. Meanwhile, the LATAM region is being targeted mainly for cultivation facilities due to its fertile lands and inexpensive costs associated with growing, as more countries view legalization with zest. ‘As more markets open, international trade begins and research and science take a front seat in the coming years,’ said John Billings, head of cultivation for The Farm Dispensary. ‘There”s no reason to think this trend will not continue. Growing plants/varietals with higher concentrate returns will help keep production costs down. You have old players (Israel, Jamaica, GW Pharmaceuticals and the U.S.) and new players (Canada and Mexico) coming into the scene with their own ideas and plans.’

Blueberries Medical Corp. (OTC: BBRRF) (CSE: BBM) earlier last week the company announced that it, ‘has entered into a letter of intent (the ‘Letter Agreement’) dated February 13, 2019 for a joint venture (the ‘Joint Venture’) with Harmony and Life S.A.S., operating as El Manantial medical centers (‘El Manantial‘).

The Joint Venture will further the development and commercialization of Blueberries” medicinal cannabis products through El Manantial”s rapidly growing patient base and collaboration with El Manantial”s team of physicians, pharmacists and technicians with deep expertise in a variety of medical areas. It will also provide a direct distribution channel to an established and rapidly growing patient by selling exclusively Blueberries” cannabis-derived products. The Company has also set out to build two BPE (Good Elaboration Practices) certified pharmacies in support of the initiative which will provide additional sales channels for Blueberries” products. Blueberries and El Manantial will also develop a treatment-focused medical education program designed to assist physicians in prescribing cannabis-based treatment plans to patients.

‘Our joint venture with El Manantial provides an outstanding opportunity for Blueberries to develop medical products and acquire patients in the Colombian market’, stated Christian Toro, Chief Executive Officer of the Company. ‘El Manantial is a respected leader in Colombia, and their focus on equitable access to medicine and patient care aligns with our goal of providing treatment to a broad spectrum of patients. The Joint Venture emphasizes communication with prescribing doctors and education of both doctors and patients which is expected to ensure that Blueberries is developing treatments that the medical community needs, and that a streamlined process is developed for the company to reach its patients.’

El Manantial is among the fastest growing networks of medical centers in Colombia, currently representing over 7,000 patients and expected to grow to over 50,000 patients over the next 36-month period as four new centers are projected to come online. This is an important development in Blueberries” strategy to acquire patients and develop treatments with cannabis products, positioning Blueberries as a leader in the Colombian medicinal cannabis product market.

‘This transaction will allow us the opportunity to work with the Blueberries team to develop new cannabis products and treatments, which can in turn be rolled out to our medical center network, offering patients the best possible care’, stated Dr. Andres Vidal, founder of El Manantial. ‘We plan for our prescribing physician education program to be an important step in supporting the widespread adoption of cannabis treatments in Colombia and globally.’ Dr. Vidal, who has control and direction over El Manantial, is also a director of Blueberries.

Pharmacy Build-Out: Blueberries will make a strategic investment of up to C$400,000 in the construction of specialized pharmacies that are BPE (Good Elaboration Practices) certified. In addition to the pharmacies owned and operated by El Manantrial, the Company-owned pharmacies will also sell cannabis and cannabis-derived products exclusively from Blueberries. Completion of the build-out of the Company”s pharmacies is expected to occur during Q3 2019.

Letter Agreement Terms: Collaborate on the research, development, and commercialization of Blueberries cannabis derived medicinal products.

Blueberries to be exclusive supplier of cannabis and cannabis-derived products to El Manantial for research and sale through their medical center network and pharmacies.

Blueberries will make a strategic investment of up to C$300,000 for the development of educational programs for the medical community to deliver to patients. The program will include certification for physicians obtained through comprehensive training, and it is expected to come online in Q2 2019.

Blueberries will invest up to C$100,000 for medical center facility upgrades to expand capacity in order to accommodate the rapidly growing patient base.

The proposed Joint Venture is subject to completion of satisfactory due diligence by each of the Company and El Manatial, and the execution of a definitive agreement.

About El Manantial: Founded in 2013 by Dr. Andres Vidal, El Manantial offers its patients the best of conventional medicine, and the best of alternative and complementary medicine, guaranteeing the best possible patient care. A diverse team of physicians and technicians of various specialties of conventional medicine, family medicine, nutrition, aesthetic medicine, homeopathic medicine, and natural medicine, bacteriologists, paramedics, pharmacists make El Manantial a leading center of medical expertise in Colombia. As one of the fastest growing medical center network in Colombia, the goal of El Manantial is to generate equitable access for all Colombians to medical treatment. The centers are actively engaged in the research and development of new and cutting-edge treatments to meet the needs of patients. For further information about El Manantial, please visit https://centromedicoelmanantial.co/.

About Blueberries Medical Corp: Blueberries is a Colombia-based licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá savannah of central Colombia. Led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries has received all licenses required for the cultivation, production, domestic distribution, and international export of CBD (cannabidiol) and THC (tetrahydrocannabinol)-based medical cannabis. Blueberries” combination of leading scientific expertise, agricultural advantages, and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.’

Innovative Industrial Properties, Inc. (NYSE: IIPR) is focused on the regulated U.S. cannabis industry.  Earlier this month the company announced that it closed on the acquisition of a property in Sacramento, California, which comprises approximately 43,000 square feet of industrial space. This acquisition marks IIP”s first investment in California and expands its portfolio to ten U.S. states. The purchase price for the Sacramento property was approximately $6.7 million (excluding transaction costs). Concurrent with the closing of the purchase, IIP entered into a long-term, triple-net lease agreement with an experienced operator, which intends to operate the property as a licensed cannabis cultivation facility in accordance with California regulations. The seller of the property is expected to complete redevelopment of the building, for which IIP has agreed to provide reimbursement of up to $4.8 million. Assuming full reimbursement for the redevelopment, IIP”s total investment in the property will be approximately $11.5 million.

Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids currently serving tens of thousands of patients in twelve countries spanning five continents. Tilray, Inc. recently announced that after completing an acquisition of its existing import and distribution partner Alef Biotechnology SpA, the company has officially relaunched as Tilray Latin America SpA, a wholly-owned subsidiary of Tilray. Tilray Latin America will further strengthen Tilray”s position as a global leader in the medical cannabis market. Tilray currently has medical cannabis products available in twelve countries and operates globally through its wholly-owned subsidiaries in Australia & New Zealand, Canada, Germany, and Portugal. Tilray Latin America will import, produce and distribute Tilray branded medical cannabis products in Chile and create a hub to distribute Tilray products throughout Latin America, subject to local laws. Tilray previously announced a partnership with Alef Biotechnology in February 2017 to import and distribute Tilray products in Chile and Brazil. Alef, now Tilray Latin America, is currently licensed by the Chilean government to commercially produce medical cannabis and is planning a state-of-the-art facility to domestically produce and process medical cannabis products. Chilean law permits patients to access medical cannabis products under the supervision of a recommending physician.

Village Farms International, Inc. (OTCQX: VFFIF) (TSX: VFF) is one of the largest and longest-operating vertically integrated greenhouse growers in North America and the only publicly traded greenhouse produce company in Canada. Village Farms International, Inc. recently announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. has entered into a credit agreement with Bank of Montreal (‘BMO’), as agent and lead lender and Farm Credit Canada as lender in respect of a CAD 20 Million secured non-revolving term loan. Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million sq. ft. greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes. ‘The ability to establish this Credit Facility with Bank of Montreal, a Canadian Schedule I bank, and Farm Credit Canada, the country”s leading agriculture lender, is a testament to the strength and potential of Pure Sunfarms,’ said Michael DeGiglio, Chief Executive Officer, Village Farms International. ‘Village Farms has long-standing relationships with both BMO and FCC, each of which, based on our extensive histories, recognizes and values our three decades of large-scale greenhouse production experience and deep expertise throughout the supply chain. We are pleased to now extend these relationships to Pure Sunfarms as it rapidly approaches full production at one of the single largest cannabis facilities in the world and begins to generate positive cash flow from operations as expected in the first quarter of 2019.’

iAnthus Capital Holdings, Inc. (OTCQX: ITHUF) (CSE: IAN) owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. iAnthus Capital Holdings, Inc. recently announced that it has opened its first and flagship dispensary in New York on December 30, 2018. The dispensary, located at 202 Flatbush Avenue directly across from Barclays Center and Atlantic Terminal, is the first in Brooklyn, New York”s largest borough, with a population of roughly 2.6 million people. The dispensary will operate under iAnthus” ‘Citiva’ New York dispensary brand. ‘The opening of our Brooklyn dispensary is a major milestone for iAnthus and Citiva. With an ideal location and an expert team in place, we expect this dispensary to be a major asset to the community and the Company,’ said Hadley Ford, Chief Executive Officer of iAnthus. ‘We are incredibly proud to be the first to open a dispensary in Brooklyn, which serves as a testament to iAnthus” track record of innovation and industry firsts.’

PharmaCielo Ltd. (OTC: PHCEF) (TSX-V: PCLO)  is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo Ltd., the Canadian parent of Colombia”s premier cultivator and producer of medicinal-grade cannabis oil PharmaCielo Colombia Holdings S.A.S., recently announced that it has received a 500-year-old ancestral cannabis strain for its exclusive use from the Arhuaco indigenous people. The Company received the Seeds as part of a traditional ceremony at the site of its nursery and propagation centre in Rionegro, Antioquia. The Seeds will be cultivated by PharmaCielo in the Arhuaco”s ancestral territory of the Sierra Nevada mountains. ‘Our team is grateful to the Arhuaco for their friendship and the trust they have placed in PharmaCielo to carry a strain of great cultural importance to the wider population of Colombia and other global markets,’ said Anthony Wile, Co-Founder and Chief Executive Officer of PharmaCielo Colombia’One of our primary objectives as a corporate leader in Colombia is to bring opportunity to historically exploited indigenous communities through the quality production of strains that have been in community use for hundreds of years. With a combination of pharmaceutical-grade cultivation and production standards, vastly scalable, low-cost production capacity and access to unique strains like that provided by the Arhuaco, PharmaCielo is positioned to be a global leader in the production and sale of medicinal-grade cannabis.’

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ”Site”) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For blueberries medical corp., financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

For further information:

info@financialbuzz.com 
+1-877-601-1879
Url: www.FinancialBuzz.com

NEW YORK, Feb. 19, 2019 /PRNewswire/ — The expansion of the cannabis industry has led companies involved in the marketplace to expand internationally as larger players are extending their operations into other regions such as Europe and Latin America. Cannabis is enjoying a global perspective shift on legalization, however, the industry is still heavily hindered by certain regulations. Nonetheless, many countries are exploring opportunities within the market for medical applications. Despite its continued global expansion, the U.S. continues to dominate the cannabis marketplace. According to Verified Market Intelligence, the global marijuana market was valued at USD 42.20 Billion in 2017 and is expected to reach USD 466.81 Billion by 2025. Additionally, the market is projected to register a CAGR of 35.3% throughout the forecast period from 2018 to 2025. The market is primarily being accelerated by the growing adoption of medical cannabis for the treatment of chronic diseases. However, as more U.S. states begin to legalize recreational cannabis, projections show that recreational sales could overtake medical sales in the near future. Blueberries Medical Corp. (OTC: BBRRF) (CSE: BBM), Innovative Industrial Properties, Inc. (NYSE: IIPR), Tilray, Inc. (NASDAQ: TLRY), Village Farms International, Inc. (OTC: VFFIF) (TSX: VFF), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN).

[[[tasteofexc

Read Full Article

Don”t miss out on business opportunities in Near Infrared Imaging Market

The growth of this market is primarily driven by the increasing number of surgical procedures globally and the advantages of NIR imaging over conventional visualization methods.

Devices segment to account for the largest share of the market in 2018

Based on product, the market is segmented into devices and reagents. In 2018, the devices segment is expected to account for a larger share of the Near Infrared Imaging Market. The rising number of surgical procedures performed due to the increasing prevalence of cancer, cardiovascular diseases, neurovascular diseases, and gastrointestinal diseases is the major factor driving the demand for near infrared imaging devices.

Browse in-depth TOC on ‘Near Infrared Imaging Market

129 – Tables

36 – Figures  

175 – Pages  

Get 10% Free Customization on this Report: 

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=174869738

Cancer surgeries segment to grow at the highest CAGR during the forecast period

Based on application, the Near Infrared Imaging Market is segmented into cancer surgeries, plastic/reconstructive surgeries, gastrointestinal surgeries, cardiovascular surgeries, preclinical imaging, and other applications. The cancer surgeries segment is expected to grow at the highest CAGR during the forecast period owing to the significant growth in the prevalence of cancer across the globe.

North America to dominate the Near Infrared Imaging Market in 2018

In 2018, North America is expected to be the largest regional market for near infrared imaging. This can primarily be attributed to the high healthcare spending, rising geriatric population, increasing prevalence of target diseases, rising number of cosmetic surgeries, and the rapid adoption of technologically advanced imaging systems in the region.

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=174869738

The key players operating in the Near Infrared Imaging Market are Stryker (US), KARL STORZ SE & Co. KG (Germany), Carl Zeiss Meditec AG (Germany), Leica Microsystems (Germany), Olympus (Japan), Fluoptics (France), Hamamatsu Photonics K.K (Japan), Quest Medical Imaging B.V. (Netherlands), Mizuho Medical Co, Ltd. (Japan), Shimadzu Corporation (Japan), Visionsense (Israel), PerkinElmer, Inc. (US), LI-COR, Inc. (US), and SurgVision (Netherlands).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/near infrared-imaging-market.asp 
Visit Our Website: https://www.marketsandmarkets.com

CHICAGO, Feb. 15, 2019 /PRNewswire/ — According to the new market research report Near Infrared Imaging Market by Product Type (NIR Fluorescence Imaging, Reagents), Application (Cancer surgery, Plastic surgery, Gastrointestinal surgery) End Users (Hospitals & Clinics, Research laboratory, Pharmaceutical companies) – Global Forecast to 2023′, published by MarketsandMarkets™, the Near Infrared Imaging Market is projected to reach USD 822 million by 2023 from an estimated USD 416 million in 2018, at a CAGR of 14.6% during the forecast period of 2018 to 2023.

[[[tasteofexc

Read Full Article

According to the new market research report Ligation Devices Market by Product (Hand-held Instruments, Accessories), Procedure (Minimally Invasive & Open Surgery), Application (Gynaecology, GIT, Cardiothoracic, Urology), End User (Hospital, Nursing Homes) – Global Forecast to 2024′, published by MarketsandMarkets™, the Ligation Devices Market is expected to reach USD 1,189 million by 2024 from USD 876 million in 2019, at a CAGR of 6.3%.

Don”t miss out on business opportunities in Ligation Devices Market

Accessories dominated the Ligation Devices Market in 2018

By product, the Ligation Devices Market is segmented into handheld instruments and accessories. In 2018, the accessories segment accounted for the largest share of the market. The large share of this product segment can be attributed to the increasing volume of surgical procedures resulting in high demand for accessories.

Browse in-depth TOC on ‘Ligation Devices Market

80 – Tables

30 – Figures  

110 – Pages  

Get 10% Free Customization on this Report: 

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=22007372

Gastrointestinal & abdominal surgeries held the largest share of the applications market in 2018

Based on applications, the Ligation Devices Market is segmented into gastrointestinal & abdominal surgeries, gynecological surgeries, cardiovascular surgeries, urological surgeries, and other applications such as wound, ENT, and cosmetic applications. In 2018, the gastrointestinal & abdominal surgeries segment accounted for the largest share of the Ligation Devices Market. The large share of this segment can be attributed to the increasing incidence of gastrointestinal cancer and the growing number of cholecystectomy and hernia treatment procedures.

Hospitals were the largest end users of ligation devices in 2018

By end user, the Ligation Devices Market is segmented into hospitals and other end users. The hospitals segment accounted for the largest market share in 2018 while the other end users segment is projected to grow at the highest CAGR during the forecast period. The large volume of surgical procedures performed in hospitals is the major factor driving the growth of this segment.

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=22007372

North America commanded the largest share of the Ligation Devices Market in 2018

North America commanded the largest share of the Ligation Devices Market. The large share of North America in this market can be attributed to the increasing prevalence of cancer and hernia, the growing number of bariatric surgeries, growing healthcare expenditure, increasing preference for MIS, and the favorable reimbursement scenario for laparoscopic surgeries.

Some of the major players in this market include Ethicon (Johnson and Johnson) (US), Teleflex Incorporated (US), Olympus (Japan), Applied Medical (US), ConMed (US), Cooper Surgical (US), Genicon (US), Grena Think Medical (UK), B.Braun (Germany), and Medtronic (Ireland).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ligation-device-market.asp 
Visit Our Website: https://www.marketsandmarkets.com

 

CHICAGO, Feb. 11, 2019 /PRNewswire/ —

[[[tasteofexc

Read Full Article

Push Doctor, the UK”s leading digital health provider, has selected Datix as its patient safety software provider, moving patient safety beyond the physical walls of the healthcare provider and into the burgeoning virtual healthcare space. Push Doctor will deploy three Datix modules – Incident, Dashboard, and Risk Register – which will enable the digital physician practice to transform its current reporting system by improving accuracy of incident reports, standardising reports, and triangulating incident and risk data to identify improvement opportunities.

Push Doctor provides digital consultations to hundreds of thousands of patients each year. Push Doctor selected Datix not only for its established expertise and credibility, but also for the patient safety best practices Datix has developed from more than 30 years of working with healthcare providers to reduce preventable patient harm.

‘A key differentiator was that the Datix system could be configured around our individual policies, processes, and culture,’ said Wais Shaifta, CEO of Push Doctor. ‘The connectivity between incident and risk data is key to us, as it will provide us with a complete overview of all of our data and allow us to more accurately pinpoint areas for improvement, something that we couldn”t do with our previous system. We”re keen to start standardising our processes and improving accuracy with Datix.’

Push Doctor”s GPs are located remotely throughout the UK, which has posed a challenge in creating a clear or easy process for reporting incidents or risks. With Datix, however, all users will now have access to an instant incident reporting function, which will improve reporting rates, accuracy, and – ultimately – safety.

The three modules being implemented will provide Push Doctor with a user-friendly system that will make for easy engagement and standardisation of best practices for the diverse background that make up the online service. Employing a strong incident management tool will mean users can focus on their specialities and automate event notification. In addition, reports will be simplified, making them easier to understand, and stored in a central repository, eliminating challenges Push Doctor has previously experienced with management reporting.

‘Datix is on the leading edge of revolutionising healthcare”s approach to patient safety, and Push Doctor is on the leading edge of transforming the healthcare delivery system – which is why we are so excited about this partnership,’ said Claire Aldred, Datix Vice President Commercial UK and EU. ‘Two innovative companies working together to enhance the fast-growing online healthcare sector will create learning opportunities that this new alliance will open up for the benefit of patients across the UK.’

About Datix 
Datix has been a global pioneer in the field of patient safety over the past three decades and today is the leading provider of software for patient safety, risk management and incident reporting for the healthcare sector.

Datix aims to build and promote a culture of safety within healthcare organisations, recruiting professionals who are passionate about improving healthcare and championing technological innovation. Datix continually invests in its software and services, maintaining a leadership position at the forefront of the worldwide patient safety movement.

Datix is focused on the health and social care sector. Its customers include public and private hospitals, primary care providers, GP surgeries, mental health and ambulance service providers. Within the UK this includes over 80% of the National Health Service. Internationally the Datix client base is growing rapidly and includes large scale deployments in the USA and Canada as well as customers in Europe, Australia and the Middle East. Datix has offices in London, Chicago and Washington DC, with partners in the Middle East, Australia and New Zealand.

About Push Doctor 
Push Doctor was the UK”s first platform to offer video consultations with patients online and via smartphone – offering quick, easy and convenient access to NHS trained doctors.

Today, Push Doctor connects thousands of patients each week with a UK GP, with appointments available in just minutes.

The service treated over 1,000 different condition types last year including a wide range of infections, gastric, respiratory and mental health conditions. 9 out of 10 people got the help they needed first time.

The brand continues to evolve to encompass a broader range of medical conditions, health, wellness and lifestyle products / services as it treats the nation, with the core goal of enabling its customers to live happier, longer lives.

LONDON, January 29, 2019 /PRNewswire/ —

[[[tasteofexc

Read Full Article